Clinical Assessment of the Treatment With Cardiac Sympathetic Blockade on Chronic Heart Failure

Inclusion Criteria: * 20-70 years old * more than 3 months of chronic heart failure history or clinical symptoms of heart failure last for more than 3 months (including acute episode of chronic heart failure), chronic heart failure diagnostic criteria refer to 2012ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure * NYHA functional class III-IV, ejection fraction ≤45% * NT-proBNP\>400ng/L Exclusion Criteria: * first episode of acute heart failure * unrepaired valvular heart disease accompanied with Hemodynamic changes * hypertrophic cardiomyopathy, pericardial disease, congenital heart disease, severe pulmonary hypertension * Second-degree type 2 or worse sinoatrial or atrioventricular block without pacemaker therapy * right heart failure caused by various diseases, respiratory failure or right heart failure induced by chronic obstructive pulmonary disease * overt renal decompensation: serum creatinine\>2.1mg/dl(186umol/L) * severe hepatic dysfunction, transaminase or alkaline phosphatase \> 3 times the upper limit of normal * Cerebral vascular accident in three months( cerebral infarction, cerebral embolism, cerebral hemorrhage,etc) * life expectancy shorter than 6 months * patients with a previous or present history of tumour or precancerous lesions confirmed by pathological examination * Spine Deformity or skin infection at puncture site * participate in any clinical drug trials in the three months * the patients who do not sign the informed consent, unable or unwilling to comply with the requirements of the protocol or unsuitable for the study